Idexx Laboratories Inc earnings per share and revenue
On 03 de nov. de 2025, IDXX reported earnings of 3.40 USD per share (EPS) for Q3 25, beating the estimate of 3.19 USD, resulting in a 6.47% surprise. Revenue reached 1.11 bilhão, compared to an expected 1.09 bilhão, with a 1.01% difference. The market reacted with a +14.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of 2.98 USD, with revenue projected to reach 1.09 bilhão USD, implying an diminuir of -12.35% EPS, and diminuir of -0.98% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
What were Idexx Laboratories Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Idexx Laboratories Inc reported EPS of $3.40, beating estimates by 6.47%, and revenue of $1.11B, 1.01% above expectations.
How did the market react to Idexx Laboratories Inc's Q3 2025 earnings?
The stock price moved up 14.84%, changed from $629.51 before the earnings release to $722.94 the day after.
When is Idexx Laboratories Inc expected to report next?
The next earning report is scheduled for 02 de fev. de 2026.
What are the forecasts for Idexx Laboratories Inc's next earnings report?
Based on 15
analistas, Idexx Laboratories Inc is expected to report EPS of $2.98 and revenue of $1.09B for Q4 2025.